Economic Burden of COVID-19: A Systematic Review
Fayolah Richards,Petya Kodjamanova,Xue Chen,Nicole Li,Petar Atanasov,Liga Bennetts,Brandon J Patterson,Behin Yektashenas,Marco Mesa-Frias,Krzysztof Tronczynski,Nasuh Buyukkaramikli,Antoine C El Khoury
DOI: https://doi.org/10.2147/CEOR.S338225
2022-04-28
ClinicoEconomics and Outcomes Research
Abstract:Fayolah Richards, 1 Petya Kodjamanova, 2 Xue Chen, 3 Nicole Li, 4 Petar Atanasov, 5 Liga Bennetts, 6 Brandon J Patterson, 1 Behin Yektashenas, 1 Marco Mesa-Frias, 7 Krzysztof Tronczynski, 8 Nasuh Buyukkaramikli, 9 Antoine C El Khoury 1 1 Janssen Global Services, Raritan, NJ, USA; 2 HEMA Amaris, Sofia, Bulgaria; 3 HEMA Amaris, Shanghai, People's Republic of China; 4 HEMA Amaris, Toronto, Canada; 5 HEMA Amaris, Barcelona, Spain; 6 HEMA Amaris, Montréal, Canada; 7 Janssen Scientific Affairs LLC, Titusville, NJ, USA; 8 EMEA Janssen, Warsaw, Poland; 9 R&D Janssen, Beerse, Belgium Correspondence: Fayolah Richards, Email Objective: To review and qualitatively synthesize the evidence related to the economic burden of COVID-19, including healthcare resource utilization and costs. Methods: A systematic review of studies that assessed the economic burden [eg, direct costs, productivity, macroeconomic impact due to non-pharmaceutical interventions (NPIs) and equity] of COVID-19 was conducted by searches in EMBASE, MEDLINE, MEDLINE-IN-PROCESS, and The Cochrane Library, as well as manual searches of unpublished research for the period between January 2020 to February 2021. Single reviewer data extraction was confirmed independently by a second reviewer. Results: The screening process resulted in a total of 27 studies: 25 individual publications, and 2 systematic literature reviews, of narrower scopes, that fulfilled the inclusion criteria. The patients diagnosed with more severe COVID-19 were associated with higher costs. The main drivers for higher costs were consistent across countries and included ICU admission, in-hospital resource use such as mechanical ventilation, which lead to increase costs of 2990.76 ± 545.98. The most frequently reported indirect costs were due to productivity losses. On average, older COVID-19 patients incurred higher costs when compared to younger age groups. An estimation of a 20% COVID-19 infection rate based on a Monte Carlo simulation in the United States led to a total direct medical cost of $163.4 billion over the course of the pandemic. Conclusion: The COVID-19 pandemic has generated a considerable economic burden on patients and the general population. Preventative measures such as NPIs only have partial success in lowering the economic costs of the pandemic. Implementing additional preventative measures such as large-scale vaccination is vital in reducing direct and indirect medical costs, decreased productivity, and GDP losses. Keywords: covid-19, economic Impact, symptom Burden, health Economics, vaccines, costs Since late 2019, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has infected more than 180 million people globally and caused more than 3.9 million deaths worldwide as of June 30th 2021. 1 The virus and the measures taken to control its spread have profoundly impacted people's lives. Since the start of the Coronavirus disease 2019 (COVID-19) pandemic, significant efforts have been made by the industry and academia to discover promising treatments and vaccines that can improve the clinical disease course and patient outcomes or prevent infection, and therefore reduce the burden to public health systems. Quantifying the economic burden of COVID-19 is an essential consideration for evaluating the value of therapeutic and preventive interventions against the COVID-19 disease. The macroeconomic impact of the COVID-19 pandemic has been overwhelming, with data from Europe showing an average of 7.4% reduction of GDP in 2020, with significant variations across countries. 2,3 The GDP losses were shown to be highly correlated with drops in employment rates, especially in regions that rely on tourism industry. Negative economic growth was just one of the unintended consequences associated with the adoption of non-pharmaceutical interventions (NPIs), such as lockdowns. Governments worldwide have all struggled in balancing the trade-offs between controlling the spread of the virus to limit the burden of the disease against the unintended economic, socioeconomic and other health consequences of the imposed NPI measures. 4 It was estimated that without adequate policy measures, the pandemic would have the most significant economic impact on those of lower income, therefore increasing poverty rates and overall inequality. 2 Similar predictions have been made by the Council of Economic Advisers to the US government, who predicted that without economic support policies, people in the lower-income bracket would have suffe -Abstract Truncated-